(VIANEWS) - The Market ended the session with MITHRA (MITRA.BR) rising 9.63% to €2.22 on Wednesday, after three sequential sessions in a row of losses. BEL 20 dropped 0.64% to €3,640.71, following the last session's downward trend on what was a somewhat down trend exchanging session today.
MITHRA's last close was €2.03, 73.32% under its 52-week high of €7.59.
About MITHRA
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.
Earnings Per Share
As for profitability, MITHRA has a trailing twelve months EPS of €-1.22.
Return on Equity
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -176.58%.
More news about MITHRA (MITRA.BR).